One reason that could explain the reduced toxicity could be that the PD1/PD-L1 checkpoint interaction takes place peripherally, i.e., at the tumor site, whereas the CTLA4/B7 interaction occurs mostly centrally, i.e., in the lymphoid organs [78]. Here, CTLA4 is linked to neoplasm.